Trials / Completed
CompletedNCT06400719
Pilot Study of AVT16 in Healthy Adult Subjects
An Open Label, Single Arm Pilot Study to Investigate the Safety and Tolerability of a Single 300mg Intravenous Dose of AVT16 in Healthy Adult Subjects Aged 18 to 55 Years Inclusive
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Alvotech Swiss AG · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a pilot study in healthy adult subjects to evaluate the safety and tolerability of AVT16 after administration of a single intravenous administration. Pharmacokinetics and immunogenicity of AVT16 will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AVT16 | Single intravenous administration of 300mg of AVT16 |
Timeline
- Start date
- 2024-05-29
- Primary completion
- 2024-11-06
- Completion
- 2024-11-06
- First posted
- 2024-05-06
- Last updated
- 2025-03-11
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT06400719. Inclusion in this directory is not an endorsement.